Loading chat...

NM SB33

Bill

Status

Introduced

1/21/2026

Primary Sponsor

Jeff Steinborn

Click for details

Origin

Senate

2026 Regular Session

AI Summary

  • Allows patients with life-threatening or severely debilitating illnesses to access individualized investigational treatments (including gene therapy, antisense oligonucleotides, and neoantigen vaccines) that are uniquely produced based on their genetic profile
  • Requires eligible patients to have exhausted FDA-approved treatment options, received a physician recommendation based on genomic analysis, and provided written informed consent acknowledging risks including potential hastened death
  • Manufacturers may provide treatments for free or charge patients for manufacturing costs; health plans and government agencies may cover costs but are not required to do so
  • Protects health care providers from professional discipline or loss of Medicare certification solely for recommending individualized investigational treatments to eligible patients
  • Limits civil liability for manufacturers and caregivers acting in good faith, and prohibits state officials from blocking patient access to these treatments

Legislative Description

Right To Try Individualized Treatments Act

Last Action

SHPAC: Reported by committee with Do Pass recommendation

2/2/2026

Committee Referrals

Committees1/21/2026

Full Bill Text

No bill text available